Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 761 to 770 of 1090 total matches.
Sarilumab (Kevzara) for Polymyalgia Rheumatica
The Medical Letter on Drugs and Therapeutics • May 13, 2024 (Issue 1702)
bioavailability, exposure to sarilumab through breast
milk is expected to be minimal.7
DRUG INTERACTIONS — IL-6 ...
The FDA has approved the interleukin (IL)-6 inhibitor
sarilumab (Kevzara – Sanofi/Regeneron) for treatment
of polymyalgia rheumatica (PMR) in adults who
had an inadequate response to corticosteroids or
cannot tolerate a corticosteroid taper. Sarilumab is
the first biologic drug to be approved for treatment
of PMR; it was previously approved for treatment of
rheumatoid arthritis.
Med Lett Drugs Ther. 2024 May 13;66(1702):77-8 doi:10.58347/tml.2024.1702c | Show Introduction Hide Introduction
Adefovir (Hepsera) for Chronic Hepatitis B Infection
The Medical Letter on Drugs and Therapeutics • Dec 09, 2002 (Issue 1145)
has no known drug interactions. As with lamivudine, use of adefovir in HIV-infected patients may promote ...
Adefovir dipivoxil (Hepsera - Gilead), a nucleotide analog, has been approved by the FDA for oral treatment of chronic active infection with hepatitis B virus (HBV). In 1999, because of concerns about renal toxicity, the FDA rejected a higher-dosage formulation of adefovir for treatment of HIV infection.
Indacaterol (Arcapta Neohaler) for COPD
The Medical Letter on Drugs and Therapeutics • Apr 30, 2012 (Issue 1389)
cannot be
ruled out) for use during pregnancy.
DRUG INTERACTIONS — Indacaterol is a substrate ...
The FDA has approved indacaterol (in´´ da ka´ ter ol; Arcapta Neohaler – Novartis), an inhaled long-acting beta2-agonist, for once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). Indacaterol is not approved for treatment of exacerbations of COPD or for treatment of asthma. It has been available in Europe as Onbrez Breezhaler since 2009.
Conjugated Estrogens/Bazedoxifene (Duavee) for Menopausal Symptoms and Prevention of Osteoporosis
The Medical Letter on Drugs and Therapeutics • Apr 28, 2014 (Issue 1441)
combination remains to be determined.
DRUG INTERACTIONS — Estrogens are metabolized
partly by CYP3A4 ...
The FDA has approved Duavee (Pfizer), a fixed-dose
combination of conjugated estrogens and the
new selective estrogen receptor modulator (SERM)
bazedoxifene, for treatment of moderate to severe
vasomotor symptoms and for prevention of osteoporosis
in postmenopausal women with an intact uterus.
Bazedoxifene is an estrogen agonist/antagonist with
estrogen-like effects on bone and antiestrogen effects
on the uterus. It is the second SERM to be approved
for prevention of osteoporosis; raloxifene (Evista, and
generics) has been available as a single agent for this
indication since...
Transdermal Fentanyl (Ionsys) for Postoperative Pain
The Medical Letter on Drugs and Therapeutics • Nov 09, 2015 (Issue 1481)
death and developmental delays
have occurred in pregnant animals given fentanyl.
DRUG INTERACTIONS ...
A patient-controlled fentanyl iontophoretic transdermal
system (Ionsys – The Medicines Company)
is now available for short-term management of acute
postoperative pain in adults requiring opioid analgesia
in the hospital. Before using Ionsys, patients must
be titrated to a comfortable level of analgesia with
another opioid formulation.
Rolapitant (Varubi) for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting
The Medical Letter on Drugs and Therapeutics • Feb 01, 2016 (Issue 1487)
.
DRUG INTERACTIONS — Rolapitant is a moderate
inhibitor of CYP2D6 and an inhibitor of breast cancer ...
The FDA has approved rolapitant (Varubi – Tesaro),
an oral substance P/neurokinin 1 (NK1) receptor
antagonist, for use with other antiemetics to prevent
delayed nausea and vomiting associated with cancer
chemotherapy in adults. It is the third substance P/NK1 receptor antagonist to be approved in the US;
aprepitant (Emend) and netupitant (only available
in combination with the 5-HT3 receptor antagonist
palonosetron as Akynzeo) were approved earlier for
prevention of both acute and delayed chemotherapy-induced
nausea and vomiting.
Ameluz for Actinic Keratoses
The Medical Letter on Drugs and Therapeutics • Dec 05, 2016 (Issue 1509)
, and bleeding must be stopped before the
gel is applied.
DRUG INTERACTIONS — Concomitant use ...
The FDA has approved a 10% nanoemulsion gel
formulation of the porphyrin-based photosensitizer
aminolevulinic acid hydrochloride (ALA; Ameluz –
Biofrontera) for use in combination with a narrowband
red light photodynamic therapy (PDT) lamp (BF-RhodoLED)
for treatment of actinic keratoses (AKs)
of mild to moderate severity on the face and scalp.
A 20% ALA solution (Levulan Kerastick) approved for
use in combination with blue light PDT (BLU-U) has
been available in the US since 2002.
An EUA for Anakinra (Kineret) for COVID-19 (online only)
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022 (Issue 1665)
of anakinra by breastfeeding women has
not been associated with adverse effects.2,13
DRUG INTERACTIONS — Use ...
The recombinant interleukin-1 (IL-1) receptor
antagonist anakinra (Kineret – Sobi) has been
granted an FDA Emergency Use Authorization
(EUA) for treatment of hospitalized adults with
confirmed COVID-19 pneumonia who require low- or
high-flow supplemental oxygen, are at risk of
progressing to severe respiratory failure, and are
likely to have elevated plasma levels of soluble
urokinase plasminogen activator receptor (suPAR).
Anakinra has been available in the US for years; it
is FDA-approved for multiple indications, including
rheumatoid arthritis. Assays for suPAR are...
Vilazodone (Viibryd) - A New Antidepressant
The Medical Letter on Drugs and Therapeutics • Jul 11, 2011 (Issue 1368)
treatment in an ICU and of
developing persistent pulmonary hypertension.7
DRUG INTERACTIONS — Concurrent ...
Vilazodone (Viibryd – Forest), a selective serotonin
reuptake inhibitor (SSRI) and partial 5-HT1A receptor
agonist, has been approved by the FDA for treatment
of depression. It has been claimed to have no sexual
side effects and not to cause weight gain.
Darolutamide (Nubeqa) for Prostate Cancer
The Medical Letter on Drugs and Therapeutics • Dec 16, 2019 (Issue 1587)
,
or cognitive disorders.
DRUG INTERACTIONS — Darolutamide is metabolized
primarily by CYP3A4, and to a lesser ...
The FDA has approved darolutamide (Nubeqa –
Bayer), an androgen receptor inhibitor, for oral
treatment of nonmetastatic castration-resistant
prostate cancer (nmCRPC). Darolutamide is the third
androgen receptor inhibitor to be approved for this
indication; apalutamide (Erleada) and enzalutamide
(Xtandi), which are also approved for use in patients
with metastatic castration-resistant prostate cancer
(mCRPC), were approved earlier.